Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference By: Tenaya Therapeutics, Inc. via Business Wire August 31, 2021 at 08:00 AM EDT Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10th at 2:45 p.m. Eastern Time/11:45 a.m. Pacific Time. About Tenaya Therapeutics Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005296/en/Contacts Investor Relations: Leone Patterson Tenaya Therapeutics IR@tenayathera.com Media: Wendy Ryan Ten Bridge Communications wendy@tenbridgecommunications.com (781) 316-4424 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference By: Tenaya Therapeutics, Inc. via Business Wire August 31, 2021 at 08:00 AM EDT Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10th at 2:45 p.m. Eastern Time/11:45 a.m. Pacific Time. About Tenaya Therapeutics Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005296/en/Contacts Investor Relations: Leone Patterson Tenaya Therapeutics IR@tenayathera.com Media: Wendy Ryan Ten Bridge Communications wendy@tenbridgecommunications.com (781) 316-4424
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10th at 2:45 p.m. Eastern Time/11:45 a.m. Pacific Time. About Tenaya Therapeutics Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005296/en/
Investor Relations: Leone Patterson Tenaya Therapeutics IR@tenayathera.com Media: Wendy Ryan Ten Bridge Communications wendy@tenbridgecommunications.com (781) 316-4424